Anti CD47 Drugs Market by Target Disease Indication (Acute Myeloid Leukemias, Non-Hodgkin Lymphoma, Colorectal Cancers, Diffuse Large B-cell Lymphoma, Myelodysplastic Syndromes, Non-Small Cell Lung Cancers, Ovarian Epithelial Cancer, Oral Muscositis, Small Cell Lung Cancers), Type of Molecule (Biologics and Small Molecule) Key Players and Key Geographical Regions (US, France, Germany, Italy, Spain, UK, Australia, China, India and Israel): Industry Trends and Global Forecasts, 2021-2035
The anti CD47 market is expected to reach USD 0.1 billion in 2023 and anticipated to grow at a CAGR of 42.9% during the forecast period 2021-2035.
According to the World Health Organization (WHO), cancer currently ranks as the second leading cause of death globally. Projections from the National Cancer Institute (NCI) suggest that by 2030, the United States alone might experience an influx of over 22 million new cases spanning various forms of cancer. This increasing patient population underscores a critical need for more effective treatments. Traditional approaches such as chemotherapy, surgery, and radiation, while pivotal, are often insufficient, particularly in cases of advanced cancers. Consequently, recent research efforts have pivoted toward exploring novel treatments like T-cell immunotherapies, which have exhibited promising efficacy. However, these therapies are not without limitations, often leading to off-target effects such as cytokine release syndrome and neurotoxicity. Consequently, substantial focus has been directed towards identifying drugs that can selectively target specific markers associated with cancer. Among these, CD47, identified at higher levels on cancer cells, has emerged as a significant immune checkpoint biomarker. Studies indicate that inhibiting the interaction between CD47 and SIRP? can effectively impede tumor growth and metastasis.
Presently, there are no approved therapies specifically targeting the CD47/SIRP? pathway for advanced cancers like myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Worldwide, researchers and developers are assessing drugs with dual capabilities, aiming to heighten efficacy and broaden the spectrum of targeted options. These candidate treatments seek to address biomarkers such as HER2, PD-L1, CD-38, CD-40, and CD-20 in conjunction with CD47. While many of these candidates are in their nascent stages of clinical development, developers express optimism about their therapeutic potential. The escalating number of research publications, patents, and ongoing clinical trials in this domain further substantiates the viability of anti-CD47 therapeutics in combating various cancers. Anticipations suggest significant growth in the market for these treatments, offering an advantageous position to pioneers in this evolving field
Report Coverage
According to the World Health Organization (WHO), cancer currently ranks as the second leading cause of death globally. Projections from the National Cancer Institute (NCI) suggest that by 2030, the United States alone might experience an influx of over 22 million new cases spanning various forms of cancer. This increasing patient population underscores a critical need for more effective treatments. Traditional approaches such as chemotherapy, surgery, and radiation, while pivotal, are often insufficient, particularly in cases of advanced cancers. Consequently, recent research efforts have pivoted toward exploring novel treatments like T-cell immunotherapies, which have exhibited promising efficacy. However, these therapies are not without limitations, often leading to off-target effects such as cytokine release syndrome and neurotoxicity. Consequently, substantial focus has been directed towards identifying drugs that can selectively target specific markers associated with cancer. Among these, CD47, identified at higher levels on cancer cells, has emerged as a significant immune checkpoint biomarker. Studies indicate that inhibiting the interaction between CD47 and SIRP? can effectively impede tumor growth and metastasis.
Presently, there are no approved therapies specifically targeting the CD47/SIRP? pathway for advanced cancers like myelodysplastic syndromes (MDS), non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). Worldwide, researchers and developers are assessing drugs with dual capabilities, aiming to heighten efficacy and broaden the spectrum of targeted options. These candidate treatments seek to address biomarkers such as HER2, PD-L1, CD-38, CD-40, and CD-20 in conjunction with CD47. While many of these candidates are in their nascent stages of clinical development, developers express optimism about their therapeutic potential. The escalating number of research publications, patents, and ongoing clinical trials in this domain further substantiates the viability of anti-CD47 therapeutics in combating various cancers. Anticipations suggest significant growth in the market for these treatments, offering an advantageous position to pioneers in this evolving field
Report Coverage
- The report conducts an analysis of the Anti-CD47 market, focusing on disease indications, molecule types, prominent market players, and key geographical regions.
- Examination of market growth drivers, restraints, opportunities, and challenges to provide a comprehensive understanding of factors influencing market dynamics.
- Assessment of potential advantages and barriers within the market, accompanied by insights into the competitive landscape among leading market players.
- Forecasting of market segment revenues across various countries for strategic insights.
- Detailed survey of the current landscape of CD47 targeting therapeutics, encompassing developmental phases, targeted diseases, therapeutic areas, molecule types, therapy modalities, biologic classifications, administration routes, and special drug designations. Additionally, comprehensive information on involved companies, establishment details, employee count, and headquarters location.
- In-depth profiles of key players in CD47 therapeutics development, including company overviews, drug candidates, financial information where available, recent progress, and future prospects.
- Analysis of completed, ongoing, and planned clinical trials for CD47 targeting therapies considering parameters such as registration year, patient enrollment, trial phases, recruitment status, leading sponsors, organizations involved, therapeutic areas, and geographical distribution.
- Review of nearly 600 scientific articles on CD47 targeting therapies based on publication year, types, therapeutic areas, target indications, and major publishing journals.
- Examination of partnerships formed between entities engaged in CD47 targeting therapies from 2016 to 2021, focusing on instances, types, geographical distribution, and active participants.
- Analysis of investment activities (venture capital, debt financing, grants, IPOs) in companies involved in anti-CD47 drugs between 2016 and 2021.
- Identification and assessment of key opinion leaders (KOLs) in the anti-CD47 drugs market based on their involvement in clinical studies and geographical mapping.
- Analysis of Twitter trends related to CD47 therapies, including popular accounts, keywords, hashtags, year-wise trends, and industry player engagement.
- Presentation of a 3-D bubble chart analysis of companies in the anti-CD47 drugs market across North America, Europe, and Asia-Pacific based on pipeline strength, portfolio diversity, and portfolio strength.
- Creation of a wind rose chart highlighting major pharmaceutical players involved in anti-CD47 drugs, showcasing parameters like therapeutics under development, phase of development, line of therapy, indications targeted, and experience years.
- Evaluation of startups established between 2011 and 2020 with fewer than 200 employees engaged in CD47 therapeutics development, focusing on parameters such as development phase, indications targeted, funding, investors, funding type, and deals made.
- Abpro
- ALX Oncology
- Apmonia Therapeutics
- Arch Oncology
- Aurigene
- Bristol Myers Squibb
- EpicentRx
- Forty Seven
- ImmuneOncia Therapeutics
- ImmuneOnco Biopharmaceuticals
- Innovent Biologics
- KAHR Medical
- Light Chain Bioscience
- Morphiex
- Trillium Therapeutics
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Target Protein
4.2.3. Analysis by Type of Biologic
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Type of Molecule and Route of Administration
4.2.6. Analysis by Line of Treatment
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Target Indication
4.2.10. Analysis by Type of Therapy
4.3. CD-47 Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Pipeline Candidates
4.3.5. Analysis by Phase of Development
4.3.6 Analysis by Regional Strength
4.3.7. Analysis by Company Size and Location of Headquarters
4.3.8. Analysis by Year of Establishment, Company Size and Location of Headquarters
5. COMPANY PROFILES
5.1. Abpro
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. ALX Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Apmonia Therapeutics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Arch Oncology
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Aurigene
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Bristol Myers Squibb
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. EpicentRx
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Forty Seven
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. ImmuneOncia Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. ImmuneOnco Biopharmaceuticals
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Innovent Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. KAHR Medical
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook
5.13. Light Chain Bioscience
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook
5.14. Morphiex
5.14.1. Company Overview
5.14.2. Financial Information
5.14.3. Product Portfolio
5.14.4. Recent Developments and Future Outlook
5.15. Trillium Therapeutics
5.15.1. Company Overview
5.15.2. Financial Information
5.15.3. Product Portfolio
5.15.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CD-47 Targeting Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Registration Year
6.3.3. Analysis by Trial Status and Trial Registration Year
6.3.4. Analysis by Number of Patients Enrolled and Phase of Development
6.3.5. Analysis by Type of Sponsor
6.3.6. Analysis by Target Patient Group
6.3.7. Analysis by Study Type
6.3.8. Analysis by Type of Masking
6.3.9. Analysis by Type of Interventional Model
6.3.10. Analysis by Primary Purpose of Trial
6.3.11. Analysis of Enrolled Patient Population by Geography
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. CD-47 Therapeutics: List of Publications
7.3.1. Analysis by Year of Publication
7.3.2. Analysis by Type of Publication
7.3.3. Analysis by Therapeutic Area
7.3.4. Analysis by Target Indication
7.3.5. Analysis by Affiliation of First Author
7.3.6. Leading Players: Analysis by Number of Publications
7.3.7. Key Journals: Analysis by Number of Publications
8. PARTNERSHIPS AND COLLABORATIONS
8.1. CD-47 Therapeutics: List of Partnerships and Collaborations
8.1.1 Cumulative Analysis by Year, 2015-2021
8.1.1. Analysis by Type of Partnership
8.1.2. Analysis by Year and Type of Partnership
8.1.3. Analysis by Type of Partner
8.1.4. Analysis by Year by Type of Partner
8.1.5. Analysis by Type of Partner andType of Partnership
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Region (Continent-wise)
8.1.7.1 Intercontinental and Intracontinental Agreements
8.1.8. Analysis by Region (Country-wise)
8.1.8.1 Local and International Agreements
9. FUNDING AND INVESTMENTS
9.1. CD-47 Therapeutics: List of Funding and Investments
9.1.1. Cumulative Analysis of Funding Instances by Year, 2015–2021
9.1.5. Analysis of Number of Instances by Type of Funding
9.1.2. Analysis of Instances by Year and Type of Funding, 2015–2021
9.1.3. Cumulative Analysis of Amount Invested by Year, 2015–2021
9.1.4. Analysis of Amount Invested by Year and Type of Funding, 2015–2021
9.1.6. Analysis of Amount Invested by Type of Funding
9.1.7. Analysis of Instances by Geography
9.1.8. Analysis of Total Amount Invested by Geography
9.1.9. Most Active Players: Analysis by Number of Instances
9.1.10. Most Active Players: Analysis by Amount Raised
9.1.11. Most Active Investors: Analysis by Number of Funding Instances,
10. KEY OPINION LEADERS
10.1. CD-47 Therapeutics: List of Key Opinion Leaders
10.1.1. Analysis by Type of Current Organization
10.1.2. Analysis by Geography
10.1.2.1. Analysis by Region (Continent-wise Distribution)
10.1.2.2. Analysis by Region (Country-wise Distribution)
10.1.3. Analysis by Number of Investigators and Current Organization
10.1.4. Analysis by Qualification of KOL
10.1.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
10.1.6. Comparison of Roots Analysis Score v/s Third Party Score
10.1.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
10.1.8. Analysis by Region
10.1.9. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
11. EMERGING TRENDS ON SOCIAL MEDIA
11.1. Chapter Overview
11.2. CD-47 Therapeutics: Trends on Twitter
11.2.1. Historical Trend in Volume of Tweets
11.2.2. Trending Words / Phrases on Twitter
11.2.3. Most Popular Drugs on Twitter
11.2.4. Most Prolific Authors on Twitter
11.2.5. Most Popular Indications
12. COMPANY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters
12.3. CD-47 Therapy Developers
12.3.1. Peer Group 1: Players based in North America
12.3.2. Peer Group 2: Players based in Europe
12.3.3. Peer Group 3: Players based in Asia-Pacific
13. BIG PHARMA PLAYERS
13.1. Chapter Overview
13.2. Methodology and Key Parameters
13.2.1. Analysis by Pipeline Strength
13.2.2. Analysis by Funding and Investments
13.2.3. Analysis by Partnerships
13.2.4. Analysis by Clinical Trials
13.2.5. Summary of Big Pharma Activity
14. START-UP HEALTH INDEXING
14.1. Chapter Overview
14.2. Start-ups Focused on CD-47 Targeting Therapeutics
14.3. Methodology and Key Parameters
14.4.1 Analysis by Location of Headquarters
14.2.3. Analysis by Pipeline Maturity
14.2.4. Analysis by Pipeline Strength
14.2.5. Analysis by Indication Diversity
14.2.6. Analysis by Capital Accrued through Investments
14.2.7. Analysis by Number of Investors
14.2.8. Analysis by Partnership Activity
14.2.9. Start-ups Health Indexing: Roots Analysis Perspective
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global CD-47 Targeting Therapeutics Market, 2021-2035
15.5. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Target Indication
15.5.1. CD-47 Targeting Therapeutics Market for Acute Myeloid Leukemia
15.5.2. CD-47 Targeting Therapeutics Market for Colorectal Neoplasms
15.5.3. CD-47 Targeting Therapeutics Market for Diffuse-Large Cell Lymphoma
15.5.4. CD-47 Targeting Therapeutics Market for Myelodysplastic Syndromes
15.5.5. CD-47 Targeting Therapeutics Market for Non-Hodgkin Lymphoma
15.5.6. CD-47 Targeting Therapeutics Market for Non-Small Cell Lung Cancer
15.5.7. CD-47 Targeting Therapeutics Market for Oral Muscositis
15.5.8. CD-47 Targeting Therapeutics Market for Ovarian Epithelial Cancer
15.5.9. CD-47 Targeting Therapeutics Market for Small Cell Lung Cancer
15.6. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Type of Molecule
15.6.1. CD-47 Targeting Therapeutics Market for Biologics
15.6.2. CD-47 Targeting Therapeutics Market for Small Molecules
15.7. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Geography
15.7.1. CD-47 Targeting Therapeutics Market in the US
15.7.2. CD-47 Targeting Therapeutics Market in France
15.7.3. CD-47 Targeting Therapeutics Market in Germany
15.7.4. CD-47 Targeting Therapeutics Market in Italy
15.7.5. CD-47 Targeting Therapeutics Market in Spain
15.7.6. CD-47 Targeting Therapeutics Market in UK
15.7.7. CD-47 Targeting Therapeutics Market in Australia
15.7.8. CD-47 Targeting Therapeutics Market in China
15.7.9. CD-47 Targeting Therapeutics Market in India
15.7.10. CD-47 Targeting Therapeutics Market in Israel
15.8. Drug-wise Sales Forecast
15.8.1. CPO-127 (Conjupro biotherapeutics)
15.8.1.1. Target Patient Population
15.8.1.2. Value Creation Analysis
15.8.2. DSP-107 (KAHR Medical)
15.8.2.1. Target Patient Population
15.8.2.2. Value Creation Analysis
15.8.3. IBI188 (Innovent Biologics)
15.8.3.1. Target Patient Population
15.8.3.2. Value Creation Analysis
15.8.4. Magrolimab (Forty Seven)
15.8.4.1. Target Patient Population
15.8.4.2. Value Creation Analysis
15.8.5. RRX-001 (EpicentRx)
15.8.5.1. Target Patient Population
15.8.5.2. Value Creation Analysis
16. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Key Historical Events related to CD47 Targeting Therapies
3.3. Application Areas
3.4. Mechanism of Action
3.5. Associated Side Effects and Likely Solutions
3.6. Key Features
3.7. Target Indications
3.8. Future Outlook
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. CD-47 Targeting Therapeutics: Market Landscape
4.2.1. Analysis by Type of Molecule
4.2.2. Analysis by Target Protein
4.2.3. Analysis by Type of Biologic
4.2.4. Analysis by Route of Administration
4.2.5. Analysis by Type of Molecule and Route of Administration
4.2.6. Analysis by Line of Treatment
4.2.7. Analysis by Phase of Development
4.2.8. Analysis by Therapeutic Area
4.2.9. Analysis by Target Indication
4.2.10. Analysis by Type of Therapy
4.3. CD-47 Therapeutics: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters
4.3.4. Analysis by Number of Pipeline Candidates
4.3.5. Analysis by Phase of Development
4.3.6 Analysis by Regional Strength
4.3.7. Analysis by Company Size and Location of Headquarters
4.3.8. Analysis by Year of Establishment, Company Size and Location of Headquarters
5. COMPANY PROFILES
5.1. Abpro
5.1.1. Company Overview
5.1.2. Financial Information
5.1.3. Product Portfolio
5.1.4. Recent Developments and Future Outlook
5.2. ALX Oncology
5.2.1. Company Overview
5.2.2. Financial Information
5.2.3. Product Portfolio
5.2.4. Recent Developments and Future Outlook
5.3. Apmonia Therapeutics
5.3.1. Company Overview
5.3.2. Financial Information
5.3.3. Product Portfolio
5.3.4. Recent Developments and Future Outlook
5.4. Arch Oncology
5.4.1. Company Overview
5.4.2. Financial Information
5.4.3. Product Portfolio
5.4.4. Recent Developments and Future Outlook
5.5. Aurigene
5.5.1. Company Overview
5.5.2. Financial Information
5.5.3. Product Portfolio
5.5.4. Recent Developments and Future Outlook
5.6. Bristol Myers Squibb
5.6.1. Company Overview
5.6.2. Financial Information
5.6.3. Product Portfolio
5.6.4. Recent Developments and Future Outlook
5.7. EpicentRx
5.7.1. Company Overview
5.7.2. Financial Information
5.7.3. Product Portfolio
5.7.4. Recent Developments and Future Outlook
5.8. Forty Seven
5.8.1. Company Overview
5.8.2. Financial Information
5.8.3. Product Portfolio
5.8.4. Recent Developments and Future Outlook
5.9. ImmuneOncia Therapeutics
5.9.1. Company Overview
5.9.2. Financial Information
5.9.3. Product Portfolio
5.9.4. Recent Developments and Future Outlook
5.10. ImmuneOnco Biopharmaceuticals
5.10.1. Company Overview
5.10.2. Financial Information
5.10.3. Product Portfolio
5.10.4. Recent Developments and Future Outlook
5.11. Innovent Biologics
5.11.1. Company Overview
5.11.2. Financial Information
5.11.3. Product Portfolio
5.11.4. Recent Developments and Future Outlook
5.12. KAHR Medical
5.12.1. Company Overview
5.12.2. Financial Information
5.12.3. Product Portfolio
5.12.4. Recent Developments and Future Outlook
5.13. Light Chain Bioscience
5.13.1. Company Overview
5.13.2. Financial Information
5.13.3. Product Portfolio
5.13.4. Recent Developments and Future Outlook
5.14. Morphiex
5.14.1. Company Overview
5.14.2. Financial Information
5.14.3. Product Portfolio
5.14.4. Recent Developments and Future Outlook
5.15. Trillium Therapeutics
5.15.1. Company Overview
5.15.2. Financial Information
5.15.3. Product Portfolio
5.15.4. Recent Developments and Future Outlook
6. CLINICAL TRIAL ANALYSIS
6.1. Chapter Overview
6.2. Scope and Methodology
6.3. CD-47 Targeting Therapeutics: List of Clinical Trials
6.3.1. Analysis by Trial Status
6.3.2. Analysis by Trial Registration Year
6.3.3. Analysis by Trial Status and Trial Registration Year
6.3.4. Analysis by Number of Patients Enrolled and Phase of Development
6.3.5. Analysis by Type of Sponsor
6.3.6. Analysis by Target Patient Group
6.3.7. Analysis by Study Type
6.3.8. Analysis by Type of Masking
6.3.9. Analysis by Type of Interventional Model
6.3.10. Analysis by Primary Purpose of Trial
6.3.11. Analysis of Enrolled Patient Population by Geography
7. PUBLICATION ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. CD-47 Therapeutics: List of Publications
7.3.1. Analysis by Year of Publication
7.3.2. Analysis by Type of Publication
7.3.3. Analysis by Therapeutic Area
7.3.4. Analysis by Target Indication
7.3.5. Analysis by Affiliation of First Author
7.3.6. Leading Players: Analysis by Number of Publications
7.3.7. Key Journals: Analysis by Number of Publications
8. PARTNERSHIPS AND COLLABORATIONS
8.1. CD-47 Therapeutics: List of Partnerships and Collaborations
8.1.1 Cumulative Analysis by Year, 2015-2021
8.1.1. Analysis by Type of Partnership
8.1.2. Analysis by Year and Type of Partnership
8.1.3. Analysis by Type of Partner
8.1.4. Analysis by Year by Type of Partner
8.1.5. Analysis by Type of Partner andType of Partnership
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Region (Continent-wise)
8.1.7.1 Intercontinental and Intracontinental Agreements
8.1.8. Analysis by Region (Country-wise)
8.1.8.1 Local and International Agreements
9. FUNDING AND INVESTMENTS
9.1. CD-47 Therapeutics: List of Funding and Investments
9.1.1. Cumulative Analysis of Funding Instances by Year, 2015–2021
9.1.5. Analysis of Number of Instances by Type of Funding
9.1.2. Analysis of Instances by Year and Type of Funding, 2015–2021
9.1.3. Cumulative Analysis of Amount Invested by Year, 2015–2021
9.1.4. Analysis of Amount Invested by Year and Type of Funding, 2015–2021
9.1.6. Analysis of Amount Invested by Type of Funding
9.1.7. Analysis of Instances by Geography
9.1.8. Analysis of Total Amount Invested by Geography
9.1.9. Most Active Players: Analysis by Number of Instances
9.1.10. Most Active Players: Analysis by Amount Raised
9.1.11. Most Active Investors: Analysis by Number of Funding Instances,
10. KEY OPINION LEADERS
10.1. CD-47 Therapeutics: List of Key Opinion Leaders
10.1.1. Analysis by Type of Current Organization
10.1.2. Analysis by Geography
10.1.2.1. Analysis by Region (Continent-wise Distribution)
10.1.2.2. Analysis by Region (Country-wise Distribution)
10.1.3. Analysis by Number of Investigators and Current Organization
10.1.4. Analysis by Qualification of KOL
10.1.5. Comparison of KOL Activeness v/s Strength (Scatter Plot)
10.1.6. Comparison of Roots Analysis Score v/s Third Party Score
10.1.7. Prominent Players: Comparison of Roots Analysis Score v/s Third Party Score
10.1.8. Analysis by Region
10.1.9. Most Active Key Opinion Leaders: Comparison of Professional Network v/s Academic Strength
11. EMERGING TRENDS ON SOCIAL MEDIA
11.1. Chapter Overview
11.2. CD-47 Therapeutics: Trends on Twitter
11.2.1. Historical Trend in Volume of Tweets
11.2.2. Trending Words / Phrases on Twitter
11.2.3. Most Popular Drugs on Twitter
11.2.4. Most Prolific Authors on Twitter
11.2.5. Most Popular Indications
12. COMPANY COMPETITIVENESS ANALYSIS
12.1. Chapter Overview
12.2. Methodology and Key Parameters
12.3. CD-47 Therapy Developers
12.3.1. Peer Group 1: Players based in North America
12.3.2. Peer Group 2: Players based in Europe
12.3.3. Peer Group 3: Players based in Asia-Pacific
13. BIG PHARMA PLAYERS
13.1. Chapter Overview
13.2. Methodology and Key Parameters
13.2.1. Analysis by Pipeline Strength
13.2.2. Analysis by Funding and Investments
13.2.3. Analysis by Partnerships
13.2.4. Analysis by Clinical Trials
13.2.5. Summary of Big Pharma Activity
14. START-UP HEALTH INDEXING
14.1. Chapter Overview
14.2. Start-ups Focused on CD-47 Targeting Therapeutics
14.3. Methodology and Key Parameters
14.4.1 Analysis by Location of Headquarters
14.2.3. Analysis by Pipeline Maturity
14.2.4. Analysis by Pipeline Strength
14.2.5. Analysis by Indication Diversity
14.2.6. Analysis by Capital Accrued through Investments
14.2.7. Analysis by Number of Investors
14.2.8. Analysis by Partnership Activity
14.2.9. Start-ups Health Indexing: Roots Analysis Perspective
15. MARKET SIZING AND OPPORTUNITY ANALYSIS
15.1. Chapter Overview
15.2. Scope and Limitations
15.3. Key Assumptions and Forecast Methodology
15.4. Global CD-47 Targeting Therapeutics Market, 2021-2035
15.5. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Target Indication
15.5.1. CD-47 Targeting Therapeutics Market for Acute Myeloid Leukemia
15.5.2. CD-47 Targeting Therapeutics Market for Colorectal Neoplasms
15.5.3. CD-47 Targeting Therapeutics Market for Diffuse-Large Cell Lymphoma
15.5.4. CD-47 Targeting Therapeutics Market for Myelodysplastic Syndromes
15.5.5. CD-47 Targeting Therapeutics Market for Non-Hodgkin Lymphoma
15.5.6. CD-47 Targeting Therapeutics Market for Non-Small Cell Lung Cancer
15.5.7. CD-47 Targeting Therapeutics Market for Oral Muscositis
15.5.8. CD-47 Targeting Therapeutics Market for Ovarian Epithelial Cancer
15.5.9. CD-47 Targeting Therapeutics Market for Small Cell Lung Cancer
15.6. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Type of Molecule
15.6.1. CD-47 Targeting Therapeutics Market for Biologics
15.6.2. CD-47 Targeting Therapeutics Market for Small Molecules
15.7. CD-47 Targeting Therapeutics Market, 2021-2035: Analysis by Geography
15.7.1. CD-47 Targeting Therapeutics Market in the US
15.7.2. CD-47 Targeting Therapeutics Market in France
15.7.3. CD-47 Targeting Therapeutics Market in Germany
15.7.4. CD-47 Targeting Therapeutics Market in Italy
15.7.5. CD-47 Targeting Therapeutics Market in Spain
15.7.6. CD-47 Targeting Therapeutics Market in UK
15.7.7. CD-47 Targeting Therapeutics Market in Australia
15.7.8. CD-47 Targeting Therapeutics Market in China
15.7.9. CD-47 Targeting Therapeutics Market in India
15.7.10. CD-47 Targeting Therapeutics Market in Israel
15.8. Drug-wise Sales Forecast
15.8.1. CPO-127 (Conjupro biotherapeutics)
15.8.1.1. Target Patient Population
15.8.1.2. Value Creation Analysis
15.8.2. DSP-107 (KAHR Medical)
15.8.2.1. Target Patient Population
15.8.2.2. Value Creation Analysis
15.8.3. IBI188 (Innovent Biologics)
15.8.3.1. Target Patient Population
15.8.3.2. Value Creation Analysis
15.8.4. Magrolimab (Forty Seven)
15.8.4.1. Target Patient Population
15.8.4.2. Value Creation Analysis
15.8.5. RRX-001 (EpicentRx)
15.8.5.1. Target Patient Population
15.8.5.2. Value Creation Analysis
16. APPENDIX 1: LIST OF COMPANIES AND ORGANIZATIONS
